High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome

Hypertension

Volumn 58, Issue 4, 2011, Pages 725-732

  Bähr, Ilse Nirmala ^a   Tretter, Patrizia ^d   Krüger, Janine ^b   Stark, Renee G ^e,f   Schimkus, Julia ^c   Unger, Thomas ^a   Kappert, Kai ^b   Scholze, Jürgen ^c   Parhofer, Klaus G ^d   Kintscher, Ulrich ^a  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b Institute of Laboratory Medicine   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f Inst fur Okologische Chem   (Germany)

Author keywords

angiotensin receptor blocker; inflammation; metabolic syndrome; monocytes; PPAR

Indexed keywords

CD163 ANTIGEN; CD36 ANTIGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOCYTE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANTIGENS, CD; ANTIGENS, CD36; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTES; PPAR GAMMA; RECEPTORS, CELL SURFACE; THIAZOLIDINEDIONES;

EID: 80053574174     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173542     Document Type: Article

References (38)

1. Goebel M, Clemenz M, Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther. 2006;4:615-629. (Pubitemid 44739598)
2. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
3. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
4. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective Pparγ-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
5. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor-γmodulators with angiotensin receptor blocking activity. Diabetes. 2005; 54:3442-3452. (Pubitemid 43334334)
6. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γactivity. Circulation. 2004;109:2054-2057. (Pubitemid 38620211)
7. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-2470. (Pubitemid 41134276)
8. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptorγligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106:523-531. (Pubitemid 30666385)
9. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21: 365-371. (Pubitemid 32199117)
10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289. (Pubitemid 41416583)
11. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care. 2001;24:392-397. (Pubitemid 32119143)
12. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets. 2008;12: 1257-1263.
13. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059-1062. (Pubitemid 41338752)
14. Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 2000;85:4224-4230. (Pubitemid 32055377)
15. Kintscher U, Marx N, Martus P, Stoppelhaar M, Schimkus J, Schneider A, Walcher D, Kummel A, Winkler R, Kappert K, Dorffel Y, Scholze J, Unger T. Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Res Clin Pract. 2010;89:209-215.
16. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, Isobe M. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPARγ. Lab Invest. 2011;91:932-944.
17. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107. (Pubitemid 39319009)
18. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457-464. (Pubitemid 39157547)
19. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.
20. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76-83. (Pubitemid 29036288)
21. Li YQ, Ji H, Zhang YH, Ding DY, Ye XL. Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 2006;373:264-270.
22. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγby Cdk5. Nature. 2010;466:451-456.
23. Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel M, Bahr IN, Hassle PL, Gust R, Fleck E, Unger T, Stawowy P, Kintscher U. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARγactivation. Hypertension. 2009;54: 738-743.
24. Matsumura T, Kinoshita H, Ishii N, Fukuda K, Motoshima H, Senokuchi T, Taketa K, Kawasaki S, Nishimaki-Mogami T, Kawada T, Nishikawa T, Araki E. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γin macrophages. Arterioscler Thromb Vasc Biol. 2011;31:1268-1275.
25. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. Circulation. 2005;111:343-348. (Pubitemid 40165342)
26. Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55:1149-1154. (Pubitemid 44215933)
27. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res. 2007;30:49-53.
28. Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41:893-898.
29. Hsueh W, Davidai G, Henry R, Mudaliar S. Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J Clin Hypertens (Greenwich). 2010;12:746-752.
30. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-γ. J Lipid Res. 2000;41:688-696.
31. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγpromotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252. (Pubitemid 28180857)
32. Zou LY, Peng CQ, Li CZ, Zhao CL, Zhu JM, Liu JL, Zhang CX. Association between hemoglobin scavenger receptor CD163 expression and coronary atherosclerotic severity in patients with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi. 2009; 37:605-609.
33. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171. (Pubitemid 32162909)
34. Nakaya K, Ayaori M, Hisada T, Sawada S, Tanaka N, Iwamoto N, Ogura M, Yakushiji E, Kusuhara M, Nakamura H, Ohsuzu F. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARγ. J Atheroscler Thromb. 2007;14:133-141.
35. de Luis DA, Conde R, Gonzalez-Sagrado M, Aller R, Izaola O, Duenas A, Perez Castrillon JL, Romero E. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp. 2010;25:275-279.
36. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, Lim SY, Lim DS. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol. 2007;100:1625-1629. (Pubitemid 350122328)
37. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2010;9:38.
38. Ono Y, Nakaya Y, Bando S, Soeki T, Ito S, Sata M. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J. 2009;50:73-83.